Nanoformulation of Talazoparib Increases Maximum Tolerated Doses in Combination With Temozolomide for Treatment of Ewing Sarcoma

Nanoformulation of Talazoparib Delays Tumor Progression and Ascites Formation in a Late Stage Cancer Model

(2019) Paige Baldwin et al.   Frontiers in Oncology

Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform

(2016) Y. Zhang et al.   MOLECULAR CANCER THERAPEUTICS

FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy

(2015) G. Kim et al.   CLINICAL CANCER RESEARCH

Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy

(2014) Edwin Choy et al.   BMC CANCER

Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program

(2014) M. A. Smith et al.   CLINICAL CANCER RESEARCH

Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma

(2014) Britta Vormoor et al.   CURRENT OPINION IN ONCOLOGY

Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program:PALB2mutation predicts exceptionalin vivoresponse to BMN 673

(2014) Malcolm A. Smith et al.   PEDIATRIC BLOOD & CANCER

BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency

(2013) Y. Shen et al.   CLINICAL CANCER RESEARCH

PARP-1 Inhibition as a Targeted Strategy to Treat Ewing's Sarcoma

(2012) J. C. Brenner et al.   CANCER RESEARCH

Systematic identification of genomic markers of drug sensitivity in cancer cells

(2012) Mathew J. Garnett et al.   NATURE

Ewing Sarcoma: Clinical State-of-the-Art

(2012) Jenny Potratz et al.   PEDIATRIC HEMATOLOGY AND ONCOLOGY

Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer

(2011) J. Chad Brenner et al.   CANCER CELL

PEGylated PLGA nanoparticles for the improved delivery of doxorubicin

(2009) Jason Park et al.   Nanomedicine-Nanotechnology Biology and Medicine

Changes in Incidence and Survival of Ewing Sarcoma Patients Over the Past 3 Decades

(2008) Natia Esiashvili et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Potentiation of Temozolomide Cytotoxicity by Poly(ADP)Ribose Polymerase Inhibitor ABT-888 Requires a Conversion of Single-Stranded DNA Damages to Double-Stranded DNA Breaks

(2008) X. Liu et al.   MOLECULAR CANCER RESEARCH